Making the preclinical case for intratumoral electroporation of DNA-based checkpoint inhibitors

This abstract has been prevented from online publishing. Please contact the author during the conference for more information. 

Authors

Liesl Jacobs (1), Elien De Smidt (1,2), Nick Geukens (2), Paul Declerck (1,2), Kevin Hollevoet (1)

Organisations

Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven - University of Leuven, Leuven, Belgium (1), PharmAbs - the KU Leuven Antibody Center, KU Leuven - University of Leuven, Leuven, Belgium (2)

Presenting author

Liesl Jacobs, PhD student, KU Leuven
liesl.jacobs@kuleuven.be
Contact us now

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners